RxDoctor Payments Data

Paul Schulz, MD

Behavioral Neurology & Neuropsychiatry · Houston, TXNPI 1184710477

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $597,511 of the $854,066 with a category attached, or 70.0%. 12 manufacturers reported payments, led by Lilly USA, LLC at 31.3% of the total.

$854,066in general payments, 2019–2025

Across 1,011 payments — averaging $844.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$267K
  • Acadia Pharmaceuticals Inc$246K
  • Eisai Inc.$243K
  • Biogen$50K
  • Eli Lilly$28K
  • Novo Nordisk AS$17K
  • plus $3K from 6 others
$13,301,819in research payments, 2019–2025

Across 376 payments — averaging $35,377 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$8.8M
  • AbbVie$1.1M
  • Novartis$1.1M
  • Genentech, Inc.$790K
  • UCB SA$693K
  • Novo Nordisk AS$482K
  • plus $361K from 3 others

What the payments were for

  • Consulting fees$120,04514%
  • Speaking & faculty fees$597,51170%
  • Travel & lodging$119,11414%
  • Food & beverage$17,3822%
  • Education$130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC267$267,250
Acadia Pharmaceuticals Inc394$246,288
Eisai Inc.277$242,586
Biogen36$49,834
Eli Lilly25$27,996
Novo Nordisk AS5$16,938
Merck1$2,558
Amneal Pharmaceuticals LLC2$231
Abbott1$196
SK Life Science, Inc.1$125
GE HealthCare1$33
UCB, Inc.1$32

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few behavioral neurology & neuropsychiatry providers in Texasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$430,361
Medicare patients
183
Services billed
242,769

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate124$595,717
LeqembiLecanemab-Irmb40$44,279
Rivastigmine91$21,250
Memantine Hcl459$19,073
Donepezil Hcl628$9,554
Galantamine Hbr81$4,822
Memantine Hcl ErMemantine Hcl32$3,459
Escitalopram Oxalate173$2,603
Divalproex Sodium ErDivalproex Sodium46$2,307
Galantamine ErGalantamine Hbr16$2,208
Quetiapine Fumarate ErQuetiapine Fumarate32$1,731
Oxcarbazepine12$1,530
Quetiapine Fumarate37$1,404
Atorvastatin Calcium87$1,234
Duloxetine Hcl51$1,201

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$246,288$595,717124 claims
Eisai Inc.Leqembi$242,586$44,27940 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few behavioral neurology & neuropsychiatry providers in Texason file to place this against a meaningful peer group, so we don't.

Other behavioral neurology & neuropsychiatry in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →